Advanced search
Publication Cover
OncoImmunology Volume 13, 2024 - Issue 1
Submit an article Journal homepage
2,571
Views
0
CrossRef citations to date
0
Altmetric
Original research

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Chia-Chi Lina Department of Oncology, National Taiwan University Hospital, Taipei, TaiwanCorrespondence[email protected]
View further author information
,
Elena Garraldab Vall d’Hebron Institute of Oncology (VHIO), Vall d´Hebron Hospital, Barcelona, SpainView further author information
,
Patrick Schöffskic Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumView further author information
,
David S. Hongd Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas and MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Lillian L. Siue Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, CanadaView further author information
,
Miguel Martinf Gregorio Marañón Hospital, Universidad Complutense, Madrid, SpainView further author information
,
Michela Maurg Oncology and Haematology Department, Università degli Studi di Modena e Reggio Emilia, Emilia-Romagna, ItalyView further author information
,
Rina Huih Department of Medical Oncology, Westmead Hospital and the University of Sydney, Sydney, AustraliaView further author information
,
Ross A Sooi Department of Haematology-Oncology, National University Cancer Institute, SingaporeView further author information
,
Joanne Chiuj Department of Medicine, Queen Mary Hospital, Hong Kong, ChinaView further author information
,
Tian Zhangk Department of Medicine, Duke Cancer Institute, Durham, NC, USAView further author information
,
Brigette Mal Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, ChinaView further author information
,
Chrisann Kyim Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Daniel SW Tann National Cancer Centre, Singapore and Duke-NUS Medical School, SingaporeView further author information
,
Philippe A. Cassiero Department of Medical Oncology, Centre Léon Bérard, Lyon, FranceView further author information
,
John Sarantopoulosp Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USAView further author information
,
Andrew Weickhardtq Medical Oncology Dept, Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Victoria, AustraliaView further author information
,
Richard D. Carvajalr Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USAView further author information
,
Jennifer Spratlins Cross Cancer Institute, University of Alberta, Edmonton, CanadaView further author information
,
Taito Esakit Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanView further author information
,
Fréderic Rollandu Department of Medical Oncology, Institut de Cancérologie de l’Ouest – Centre René Gauducheau, Nantes, FranceView further author information
,
Wallace Akerleyv Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USAView further author information
,
Barbara Deschler-Baierw Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, GermanyView further author information
,
Lawrence Rispolix Novartis Institutes for BioMedical Research, Cambridge, MA, USAView further author information
,
Tanay S. Samanty Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Niladri Roy Chowdhuryy Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Daniel Gusenleitnerx Novartis Institutes for BioMedical Research, Cambridge, MA, USAView further author information
,
Eunice L. Kwakx Novartis Institutes for BioMedical Research, Cambridge, MA, USAView further author information
,
Vasileios Askoxylakisx Novartis Institutes for BioMedical Research, Cambridge, MA, USAView further author information
&
Filippo De Braudz Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy and Oncology and Hemato-oncology Department, University of Milan, Milan, ItalyView further author information
 show all
Article: 2290787 | Received 13 Jun 2023, Accepted 29 Nov 2023, Published online: 20 Dec 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.